11 citations
,
May 2010 in “Journal of Medicinal Chemistry” This study introduced a novel nonsteroidal androgen receptor antagonist that effectively controls sebum production in the golden Syrian hamster ear model through targeted follicular delivery.
7 citations
,
April 2009 in “Bioorganic & Medicinal Chemistry Letters” Diphenyl ethers can potentially reduce excess oil production when applied on the skin, helping treat conditions like acne.
11 citations
,
March 2009 in “Bioorganic & Medicinal Chemistry Letters” This study reports that 4-(alkylthio)- and 4-(arylthio)-benzonitriles showed moderate sebum reduction as androgen receptor antagonists when applied topically in a validated animal model.
23 citations
,
October 2008 in “Journal of medicinal chemistry” This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.
14 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” This study reported that the compound (1R, 2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile effectively stimulated hair growth in mice and reduced sebum production in hamsters.
11 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” This study found that among the tested analogs, compound 4e was the most effective in inhibiting wax esters in vivo in the Golden Syrian hamster ear model.
17 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” This study found that a specific amino-pyridine compound showed potent androgen receptor antagonist activity, stimulating hair growth in mice and reducing sebum production in a hamster model.
62 citations
,
May 1997 in “Journal of Pharmaceutical Sciences” This study concluded that sebaceous glands are the main pathway for the antiandrogen RU 58841 to permeate the skin, with liposomes enhancing localization in these glands.
19 citations
,
July 1990 in “Cleveland Clinic journal of medicine” This article reviews endocrine therapies for androgen excess disorders, emphasizing spironolactone, estrogen, and dexamethasone as effective treatments; it reports no new clinical results.